CRISPR and Type 1 Diabetes

CRISPR technology, a powerful gene-editing tool, holds significant promise for the treatment of Type 1 Diabetes (T1D). Researchers are exploring its potential to modify or replace defective genes responsible for autoimmune attacks on insulin-producing beta cells in the pancreas. One approach involves using CRISPR to correct genetic mutations in the immune system, potentially preventing the immune response that destroys these cells. Another promising application is the use of CRISPR to enhance stem cell therapy, enabling the generation of insulin-producing cells from pluripotent stem cells. While clinical applications are still in early stages, CRISPR's ability to precisely target and edit genes offers hope for a long-term cure, rather than just symptom management, in Type 1 Diabetes.

    Related Conference of CRISPR and Type 1 Diabetes

    February 09-10, 2026

    20th International Conference on Endocrinology, Diabetes and Metabolism

    Singapore City, Singapore
    February 12-13, 2026

    5th Global Summit on Physiology and Metabolism of Thyroid

    Singapore City, Singapore
    February 23-24, 2026

    19th International Summit on Diabetes

    London, UK
    February 25-26, 2026

    16th World Congress on Endocrinology and Diabetes

    Paris, France
    March 26-27, 2026

    7th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands
    May 14-15, 2026

    7th World Summit on Diabetes

    Rome, Italy
    May 18-19, 2026

    57th Annual Congress on Endocrinology and Diabetes Research

    Aix-en-Provence, France
    August 17-18, 2026

    4th World congress and Expo on Diabetes

    Toronto, Canada

    CRISPR and Type 1 Diabetes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in